Ohga S, Nomura A, Takada H, Hara T. The immunologi- cal aspects of Epstein-Barr virus infection. Crit Rev Oncol Hematol 2002;44:203-15.
Middeldorp JM, Brink AATP, van den Brule AJC, Meijer CJLM. Pathogenic roles for Epstein_/Barr virus (EBV) gene products in EBV-associated proliferative disorder. Crit Rev Oncol Hematol 2002;44:1-36.
Vasef M, Ferlito A, Weiss L. Nasopharyngeal carcinoma with emphasis on its relationship to Epstein-Barr virus. Ann Otol Rhinol Larynol 1997;106:348-56.
Hsu MM, Hsu HC, Liu LT. Local immune reaction in naso- pharyngeal carcinoma with special reference to its prog- nostic evaluation. Head Neck 1989;11:505-10.
Lai FM, Cheng PN, Tsao SY, Lai KN. Immunohistological characteristics of the infiltrating lymphoid cells and the expression of HLA class I and II antigens in nasopharyngeal carcinoma. Virchow Arch A Pathol Anat Histopathol 1990; 417:347-52.
Lu JJY, Chen CL, Hsu TY et al. Expression of Epstein-Barr virus latent membrane protein 1 and B-cell leukemia- lymphoma 2 gene in nasopharyngeal carcinoma tissues. J Microbiol Immunol Infect 2002;35:136-40.
Long HM, Haigh TA, Gudgeon NH et al. CD4+ T-cell re- sponses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV –transformed lymphoblastoid cell lines. J Virol 2005;79:4896-907.
Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion gly- coproteins. J Exp Med 2006;203:995-1006.
Zanussi S, Vaccher E, Caffau C et al. Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcino- ma of nasopharyngeal type. Cancer Immunol Immunother 2003;52:28-32.
Ferradini L, Miescher S, Stoeck M et al. Cytotoxic poten- tial despite impaired activation pathways in T lympho- cytes infiltrating nasopharyngeal carcinoma. Int J Cancer 1991;47:362-70.
Yao M, Ohshima K, Suzumuya J, Kume T, Shiroshita T, Kikuchi M. Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1997;72:398-402.
Khanna R. Busson P. Burrows SR et al. Molecular charac- terization of antigen-processing function in nasopharyn- geal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res 1998;58:310-4.
CD4, CD8 and MHC class I expression in Epstein-Barr virus-associated nasopharyngeal carcinoma: an immunohistochemical study
Ohga S, Nomura A, Takada H, Hara T. The immunologi- cal aspects of Epstein-Barr virus infection. Crit Rev Oncol Hematol 2002;44:203-15.
Middeldorp JM, Brink AATP, van den Brule AJC, Meijer CJLM. Pathogenic roles for Epstein_/Barr virus (EBV) gene products in EBV-associated proliferative disorder. Crit Rev Oncol Hematol 2002;44:1-36.
Vasef M, Ferlito A, Weiss L. Nasopharyngeal carcinoma with emphasis on its relationship to Epstein-Barr virus. Ann Otol Rhinol Larynol 1997;106:348-56.
Hsu MM, Hsu HC, Liu LT. Local immune reaction in naso- pharyngeal carcinoma with special reference to its prog- nostic evaluation. Head Neck 1989;11:505-10.
Lai FM, Cheng PN, Tsao SY, Lai KN. Immunohistological characteristics of the infiltrating lymphoid cells and the expression of HLA class I and II antigens in nasopharyngeal carcinoma. Virchow Arch A Pathol Anat Histopathol 1990; 417:347-52.
Lu JJY, Chen CL, Hsu TY et al. Expression of Epstein-Barr virus latent membrane protein 1 and B-cell leukemia- lymphoma 2 gene in nasopharyngeal carcinoma tissues. J Microbiol Immunol Infect 2002;35:136-40.
Long HM, Haigh TA, Gudgeon NH et al. CD4+ T-cell re- sponses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV –transformed lymphoblastoid cell lines. J Virol 2005;79:4896-907.
Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion gly- coproteins. J Exp Med 2006;203:995-1006.
Zanussi S, Vaccher E, Caffau C et al. Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcino- ma of nasopharyngeal type. Cancer Immunol Immunother 2003;52:28-32.
Ferradini L, Miescher S, Stoeck M et al. Cytotoxic poten- tial despite impaired activation pathways in T lympho- cytes infiltrating nasopharyngeal carcinoma. Int J Cancer 1991;47:362-70.
Yao M, Ohshima K, Suzumuya J, Kume T, Shiroshita T, Kikuchi M. Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1997;72:398-402.
Khanna R. Busson P. Burrows SR et al. Molecular charac- terization of antigen-processing function in nasopharyn- geal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res 1998;58:310-4.
Budiani, D. R., Haryana, S. M., Soesatyo, M. . . H., Sosroseno, W. (2010). CD4, CD8 and MHC class I expression in Epstein-Barr virus-associated nasopharyngeal carcinoma: an immunohistochemical study. European Journal of General Medicine, 7(3), 277-281.
AMA
Budiani DR, Haryana SM, Soesatyo MH, Sosroseno W. CD4, CD8 and MHC class I expression in Epstein-Barr virus-associated nasopharyngeal carcinoma: an immunohistochemical study. European Journal of General Medicine. Eylül 2010;7(3):277-281.
Chicago
Budiani, Dyah R, Sofia M Haryana, Marsetyawan Hne Soesatyo, ve Wihaskoro Sosroseno. “CD4, CD8 and MHC Class I Expression in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: An Immunohistochemical Study”. European Journal of General Medicine 7, sy. 3 (Eylül 2010): 277-81.
EndNote
Budiani DR, Haryana SM, Soesatyo MH, Sosroseno W (01 Eylül 2010) CD4, CD8 and MHC class I expression in Epstein-Barr virus-associated nasopharyngeal carcinoma: an immunohistochemical study. European Journal of General Medicine 7 3 277–281.
IEEE
D. R. Budiani, S. M. Haryana, M. . . H. Soesatyo, ve W. Sosroseno, “CD4, CD8 and MHC class I expression in Epstein-Barr virus-associated nasopharyngeal carcinoma: an immunohistochemical study”, European Journal of General Medicine, c. 7, sy. 3, ss. 277–281, 2010.
ISNAD
Budiani, Dyah R vd. “CD4, CD8 and MHC Class I Expression in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: An Immunohistochemical Study”. European Journal of General Medicine 7/3 (Eylül 2010), 277-281.
JAMA
Budiani DR, Haryana SM, Soesatyo MH, Sosroseno W. CD4, CD8 and MHC class I expression in Epstein-Barr virus-associated nasopharyngeal carcinoma: an immunohistochemical study. European Journal of General Medicine. 2010;7:277–281.
MLA
Budiani, Dyah R vd. “CD4, CD8 and MHC Class I Expression in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: An Immunohistochemical Study”. European Journal of General Medicine, c. 7, sy. 3, 2010, ss. 277-81.
Vancouver
Budiani DR, Haryana SM, Soesatyo MH, Sosroseno W. CD4, CD8 and MHC class I expression in Epstein-Barr virus-associated nasopharyngeal carcinoma: an immunohistochemical study. European Journal of General Medicine. 2010;7(3):277-81.